A Novel N7-Methylguanosine-Related lncRNA Signature Predicts the Prognosis of Colon Adenocarcinoma Patients

Abstract

Background: The most common subtype of colorectal cancer is colon adenocarcinoma (COAD). However, few studies have investigated the predictive value of N7-methylguanosine(m7G)-related long-noncoding RNAs (lncRNAs) in COAD. We aim to use m7G-related lncRNAs to construct a prognostic model for COAD.Methods: RNA-seq data and the corresponding clinical and prognostic Data were downloaded from The Cancer Genome Atlas (TCGA) database.M7G-related lncRNAs with prognostic values were identified using the univariate and multivariate Cox regression. Based on Kaplan-Meier curves, we compared the survival rates in the high-risk and low-risk groups. The functional enrichment of m7G-related lncRNAs with a prognostic value was interpreted using gene set enrichment analysis (GSEA). Finally, we studied the relationship between predictive signature and treatment response in patients with COAD.Results: Six m7G-related lncRNAs (LINC01063, ARRDC1-AS1, AL354993.2, ZEB1-AS1, SNHG16, LINC02474) were identified to establish a signature. The m7G-related lncRNA signature may be able to predict COAD patients' prognosis independently. The OS times of patients in the high-risk group were shorter than those in the low-risk group. With an area under the receiver operating characteristic curve of 0.742, the m7G-related lncRNA prognostic signature had a better prognostic prediction than clinicopathological variables. The high-risk group has the most tumor-related pathways, according to GSEA. The prognostic characteristic was linked to the immunological state of COAD patients, according to GSEA. The conventional chemotherapy medicines axitinib, cytarabine, sorafenib, parthenolide and vorinostat were more sensitive in high-risk individuals.Conclusion: Our study develops a COAD risk model consisting of six lncRNAs related to m7G that have independent prognostic values. Clinically, the lncRNA signature could improve prediction of outcomes for patients with COAD and, with further prospective validation, could help guide tailored therapy for COAD patients